We rarely get feed back on episodes of Freely Filtered. That is until we screw up. And our episode on the PRAECIS trial did not go smoothly. So we went back and re-recorded a podcast. So join us as we re-examine the newly FDA-approved blood test looking at the ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) for the diagnosis of severe preeclampsia. The PRAECIS trial.

Nefecon, coated budesonide, is the first drug labelled for IgA nephropathy and the approval path, 9-month reduction in proteinuria followed by 2 year GFR data set the stage for the GN renaissance we are currently living through.

On May 24th, at the ERA meeting in Stockholm Sweden (this will not be the last GLP1ra talk at Stockholm), Vlado Perkovic presented the previously spoiled results of FLOW. In addition to simultaneous publication in the NEJM, it made the front page in newspapers around the world. As one headline writer said, “Is there anything Ozempic can’t do?”

Preeclampsia is scarry. Wouldn’t be great if we a blood test to predict which patients would develop severe pre-eclampsia? Well maybe, just maybe the sFlt-1 to PlGF ratio could answer this prayer.